- Oops!Something went wrong.Please try again later.
Preclinical work for the prophylactic vaccine, invented and developed at Cleveland Clinic, is ongoing with support from the National Cancer Institute's PREVENT Program
SAN JOSE, Calif., Jan. 25, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the Japanese Patent Office has issued a Decision to Grant of a patent to Cleveland Clinic titled, "Ovarian Cancer Vaccines." The technology was invented by Drs. Vincent K. Tuohy, Suparna Mazumder and Justin M. Johnson at Cleveland Clinic. Anixa is the worldwide licensee for the vaccine technology. Patents for the technology were issued in the U.S. and Europe in 2021.
"We're pleased to announce this additional intellectual property protection of Anixa's novel ovarian cancer vaccine, which was developed at Cleveland Clinic and is being studied at NCI. This unique technology has the potential to be the first vaccine to prevent ovarian cancer, which remains one of the most devastating and difficult-to-treat cancers," said Dr. Amit Kumar, CEO, President and Chairman of Anixa Biosciences. "If successful, this vaccine could prevent ovarian cancer from ever occurring and spare patients from undergoing chemotherapy and extensive surgical treatments, and potentially save lives. We look forward to continuing our preclinical work in the hope that this vaccine will add to the arsenal needed to target this challenging cancer and ultimately make a difference for many patients."
The ovarian cancer vaccine targets the extracellular domain of anti-Müllerian hormone receptor 2 (AMHR2-ED), which is expressed in the ovaries but disappears as a woman reaches and advances through menopause. Of note, the majority of ovarian cancer diagnoses occur after menopause, and AMHR2-ED is expressed again in the majority of ovarian cancers. By receiving a vaccine such as Anixa's that targets AMHR2-ED after reaching menopause, ovarian cancer, historically one of the most aggressive gynecological cancers, could be prevented from ever developing.
Preclinical work to advance the vaccine is ongoing through the PREVENT Program at the National Cancer Institute (NCI), which supports preclinical innovative interventions and biomarkers for cancer prevention and interception. Preclinical data published in Cancer Prevention Research in 2017 supports ongoing advancement toward clinical studies.
About Anixa Biosciences, Inc.
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a COVID-19 therapeutics program focused on inhibiting certain viral protein function. The company's vaccine portfolio includes a vaccine to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – and a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against specific proteins that have been found to be expressed in certain forms of cancer. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Chief Operating Officer and Chief Financial Officer
Slavena Salve Nissan, M.D.
LifeSci Advisors, LLC
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-japanese-patent-on-ovarian-cancer-vaccine-301467502.html
SOURCE Anixa Biosciences, Inc.